A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Official Title

An Open-Label, Multicentre, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Summary:

This first-in-human, open-label, multicentre, Phase Ia/Ib, adaptive, multiple ascending-dose study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumour activity of RO6874281 as a single agent (Part A) or in combination with trastuzumab or cetuximab (Part B or C).

Trial Description

Primary Outcome:

  • Percentage of Participants With Dose-Limiting Toxicities (DLTs)
  • Maximum Tolerated Dose (MTD) of RO6874281
  • Optimal Biological Dose (OBD) of RO6874281
  • Recommended Dose for Further Development of RO6874281
  • Systemic Clearance (CL) of RO6874281
  • Volume of Distribution at Steady State (Vss) of RO6874281
  • Area Under the Concentration-Time Curve (AUC) of RO6874281
  • Maximum Observed Serum Concentration (Cmax) of RO6874281
Secondary Outcome:
  • Number of T Cells in the Peripheral Blood
  • Number of Natural Killer (NK) Cells in the Peripheral Blood
  • Density of Cluster of Differentiation (CD)8+ Cells in Tumour Samples
  • Density of CD3-/Perforin+ Cells in Tumour Samples
  • Density of CD20 Cells in Tumour Samples
  • Percentage of Participants With Overall Response According to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)
  • Percentage of Participants With Disease Control According to RECIST v1.1
  • Progression-Free Survival (PFS) According to RECIST v1.1
  • Percentage of Participants With Overall Response According to Modified RECIST
  • Percentage of Participants With Disease Control According to Modified RECIST
  • PFS According to Modified RECIST
  • Percentage of Participants With Overall Response According to iRECIST
  • Percentage of Participants With Disease Control According to iRECIST
  • PFS According to iRECIST

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society